Gemfibrozil Ingestions Reported to Texas Poison Control Centers, 2000–2005

Abstract

Review of the literature failed to identify any information on potentially adverse ingestions of the cholesterol-lowering drug gemfibrozil (GEM) reported to poison control centers. Data from Texas poison control centers were used to describe the pattern of isolated GEM ingestions reported during 2000–2005. A total of 118 cases were identified. The mean maximum dose ingested was 2407 mg (range 300–18,000 mg) or 3.3 tablets/capsules (range 1–30 tablets/capsules). The patient was male in 55% of the cases. The most common circumstances of the exposure were unintentional therapeutic error (49%), general unintentional (34%), and suspected attempted suicide (11%). The management site was on site (84%), already at/en route to a health care facility (10%), referred to a health care facility (5%), and other (2%). The ingestion considered potentially toxic in 3% of the cases and no deaths were reported. A specific adverse clinical effect was listed for 9% of the cases, being gastrointestinal (5%), neurological (3%), or cardiovascular (1%). A specific treatment was listed for 54% of the cases, most frequently decontamination by dilution (39%) or food (15%). Potentially adverse isolated GEM ingestions reported to poison control centers generally do not involve serious medical outcomes and are successfully managed at home with a favorable outcome.

Funding for this research was provided by a contract with the Commission on State Emergency Communications in Texas. I thank the staff of the six poison control centers (Central Texas Poison Center, North Texas Poison Center, Texas Panhandle Poison Center, South Texas Poison Center, Southeast Texas Poison Center, West Texas Regional Poison Center) of the Texas Poison Center Network, who collected the data.